ClinicalTrials.gg
Not yet recruitingNCT05593224Updated Oct 25, 2022

The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis

An interventional study of Intracranial Stent (Tonbridge) in Intracranial Atherosclerosis, sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd.. Not yet recruiting at 14 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-25.

Sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2023, 3 years ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.

Planned enrollment
18th of 27
156 · median 200
Started
2022
with 3 others
No phase
16 of 44
8 open now
Primary completion
2023-11
later than 0 of 27 live
Registered
20th of 44
by date

Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 16 with no phase, reaches primary completion later than 0 of the 27 other live ones, and was the 20th registered.

Intracranial Arteriosclerosis

103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.

Browse Intracranial Arteriosclerosis studies →

Open to participants now

28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Intracranial Arteriosclerosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of intracranial atherosclerotic stenosis.

Read the detailed description

This is a prospective, multicenter, single-arm clinical trial carried out in 14 centers throughout China. 156 subjects with intracranial atherosclerotic stenosis will be treated with the Intracranial Stent (Tonbridge) for the expansion of vascular stenosis site. The primary objective of this study is to evaluate the effectiveness and safety of the intracranial stent for endovascular treatment of intracranial atherosclerotic stenosis.

03

Conditions studied

  • Intracranial Atherosclerosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75
  • Subjects with symptomatic intracranial atherosclerotic stenosis who do not respond to antiplatelet therapy or have poor compensation of collateral circulation and hypoperfusion in the offending vessel blood supply
  • The last onset time of is not limited or the last onset of ischemic stroke is more than 2 weeks
  • The lesion is confirmed to be located in intracranial large arteries, including intracranial segment of the internal carotid artery, middle cerebral artery, intracranial segment of vertebral artery and the basilar artery
  • Target vessel diameter≥2.0mm and ≤4.5mm, lesion length ≤33mm
  • Stenosis degree of intracranial arteries≥70% and ≤99% measured by intracranial angiography (WASID method)
  • Intracranial artery stenosis which requiring interventional treatment is a single lesion
  • Subjects have at least 1 atherosclerotic plaque risk factor including hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, obesity, and smoking history
  • mRS≤2 before enrollment
  • Voluntarily participate in this study and sign the form, can complete examinations and follow-ups in accordance with the requirements of the protocol during the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Intracranial arterial stenosis caused by non-atherosclerotic lesions: such as arterial dissection, moyamoya disease, vasculitis, active arteritis, etc.
  • Preoperative MRI shows only perforator infarction in the target lesion
  • Preoperative CT or MRI indicates the presence of post-infarct hemorrhagic transformation in the target vascular, or a history of subarachnoid, subdural, and epidural hemorrhage within 30 days before procedure, or the presence of untreated chronic subdural hematoma (≥5mm)
  • Severe calcification of target vessels; or target vessel tortuosity or other reasons will make experimental device difficult to reach the target lesion position
  • There is more than 70% stenosis in the distal intracranial large vessels or proximal intracranial and extracranial large vessels of the target vessels, and the presence of unidentified responsible lesions
  • Subjects have a major surgery within 30 days before procedure or intend to be hospitalized for other procedure within 6 months after procedure
  • Intracranial tumors or intracranial arteriovenous malformations, or distal and proximal target vessels combined with aneurysms
  • The target lesion has a history of stent implantation
  • It is suspected that there is severe allergy or to aspirin, clopidogrel, heparin, contrast media, nitinol and other drugs and devices related to endovascular therapy
  • There is an underlying source of cardiac thrombus, such as atrial fibrillation, left ventricular thrombus, myocardial infarction within 30 days
  • Subjects with an > 1.5 or the presence of nonmodifiable bleeding factors
  • Medically uncontrolled severe hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg)
  • Severe comorbid conditions or unstable conditions, such as severe heart failure, pulmonary failure, or renal failure (serum creatinine >3.0 mg/dL (264μmol/L)), severe liver insufficiency ( or AST >3 times normal), and
  • is less than two years
  • Women who are pregnant or breastfeeding
  • Subjects unable to complete follow-up due to cognitive impairment, mood disorder, or mental illness
  • Subjects who are enrolled in other clinical trials of drugs/devices and have not yet met the primary endpoint
  • Other circumstances which investigators do not consider are appropriate for intracranial stent treatment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Intracranial Stent (Tonbridge)

    Placement of Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd. ).

    Device: Intracranial Stent (Tonbridge)

Interventions

  • DeviceIntracranial Stent (Tonbridge)

    The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.

06

What researchers measure

Primary outcomes

  1. Incidence of in-stent restenosis at 6 months

    The in-stent restenosis is defined as more than 50% stenosis within stent or distal/proximal ends (within 5 mm), and more than 20% absolute lumen loss. The degree of intracranial artery stenosis are measured qualitatively in DSA examination. WASID study will be used to measure the degree of intracranial artery stenosis.

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Device success rate and procedural success rate

    Device success refers to the successful delivery of the stent to the lesion site through the delivery system during procedure, and it is released smoothly and fits well with the vessel wall without bending and displacement; procedural success is defined as stenosis degree less than 30% immediately after procedure.

    Time frame: Intraoperation

  2. Incidence of symptomatic in-stent restenosis at 6 months, 1 year, and 2 years

    Symptomatic in-stent restenosis is defined as ischemic stroke or TIA or other ischemic neurological symptoms which are caused by in-stent restenosis.

    Time frame: 6 months, 1 year, and 2 years post-procedure

  3. Ratio of mRS 0-2 at 30 days, 6 months, 1 year, and 2 years

    Subjects will be evaluated at the follow-up visits according to the mRS. The mRS 0-2 indicates a good prognosis.

    Time frame: 30 days, 6 months, 1 year, and 2 years post-procedure

  4. Incidence of stent restenosis at 1 and 2 years

    Restenosis is defined as more than 50% stenosis within stent or distal/proximal ends (within 5 mm), and more than 20% absolute lumen loss.

    Time frame: 1 and 2 years post-procedure

  5. Incidence of any stroke and death within 30 days

    Stroke includes both ischemic and hemorrhagic strokes. Deaths from any cause are included in this data.

    Time frame: Within 30 days post-procedure

  6. Mortality at 31 days to 6 months, 6 to 12 months, and 12 to 24 months

    Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure

  7. Incidence of ischemic stroke in the target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months

    Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure

  8. Incidence of ischemic stroke in non-target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months

    Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure

  9. The incidence of any hemorrhagic stroke at 31 days to 6 months, 6 to 12 months, and 12 to 24 months

    Time frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure

  10. Incidence of device deficiency

    Device deficiency is the unreasonable risk that may endanger human health or life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems, malfunctions, etc. Possible device deficiency: labeling errors, product quality problems, design defects, broken sterilization packaging, etc.

    Time frame: After use of device to end of study

  11. Incidence of adverse events (AE) at 30 days, 6 months, 1 year, and 2 years

    Time frame: Through 2 years post-procedure

  12. Incidence of serious adverse events (SAE) at 30 days, 6 months, 1 year, and 2 years

    Time frame: Through 2 years post-procedure

07

Study locations

14 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for Nov 2023, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 25, 2022
StartEst.
Nov 2022
Primary completionEst.
Nov 2023
CompletionEst.
May 2025
Last update
Oct 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05593224
Lead sponsor
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Responsible party
Sponsor
First posted
Oct 25, 2022
Start date
Nov 2022 (estimated)
Primary completion
Nov 2023 (estimated)
Completion
May 2025 (estimated)
Last update
Oct 25, 2022

Study contacts

Long Chen
Contact
long.chen@ton-bridge.com
13868091267
Yuhan Yan
Contact
yh.yan@ton-bridge.com
15843291055
Jianmin Liu
principal investigator · Changhai Hospital
Shouchun Wang
principal investigator · The First Hospital of Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion